Tesamorelin Acetate (TH9507) supplied as a research-use raw material — bulk lyophilized powder by gram or lyophilized vial — for qualified B2B sourcing projects. >99.3% by HPLC, acetate form (CAS 901758-09-6), with batch-specific COA, HPLC purity and LC-MS identity. Research-grade as standard; API-grade available under a signed quality agreement. Not for clinical, therapeutic, compounding, injection, or direct-to-consumer use.
Key Review Snapshot
Typical Applications
MOQ / Lead Time / Samples
Why buyers trust WUMO
In this market, “99% pure” is often quoted while the amount actually delivered is far less. We keep purity and real content separate, and put both on paper — so Tesamorelin Acetate (TH9507) — Research-Use Raw Material & Lyophilized Vial is backed by documents you can check.
Research peptide line — typical purity >99.3–99.4%, every batch MS-checked before release.
Purity (%) and content (the actual amount delivered) are not the same thing. We document both, so the amount on the label is the amount you receive — no quiet shortfalls.
Identity and quality are confirmed by batch documentation — COA, plus HPLC / MS where applicable — before material is released.
Ingredient identity (INCI / CAS), specification sheet and SDS are available for review. Match the documents to your quoted batch before you commit.
Overview
Tesamorelin Acetate (TH9507) is a synthetic 44-amino-acid GHRH-analog peptide, supplied here as a research-use raw material for qualified B2B buyers. It is available as bulk lyophilized powder (by gram) or in lyophilized vial format, with batch-specific documentation, specification review, and packaging discussion.
Material is acetate form (CAS 901758-09-6; free base 218949-48-5), >99.3% by HPLC, with LC-MS identity confirmed against the target mass (~5135.9 Da free-base equivalent; acetate salt basis ~5196 Da). Research-grade is standard; API-grade is available under a signed quality agreement. Typical lead time is approximately 20 days, subject to batch and order scope.
This page is intended for B2B sourcing and laboratory research-use communication only. It does not provide medical advice, dosage guidance, injection instructions, or therapeutic claims. WUMO Peptide is not affiliated with any branded tesamorelin drug product.
B2B Review Guide
Tesamorelin Acetate is offered by WUMO Peptide as a research-use raw material — bulk lyophilized powder by gram, or lyophilized vial format — for qualified B2B sourcing projects. It is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH / GRF(1-44)) and is discussed in laboratory research contexts involving peptide identity, purity, and analytical documentation.
Two CAS numbers appear in the market: 901758-09-6 (acetate, the form supplied here) and 218949-48-5 (free base). The widely quoted ~5135.9 Da is the free-base equivalent; the acetate salt basis is ~5196 Da. Confirm the salt form and the molecular-weight basis on the batch COA so that quotes and LC-MS results reconcile. Purity is >99.3% by HPLC, with peptide content reviewed separately from purity.
For B2B customers, the key review points are batch-specific specification, HPLC purity, LC-MS identity, documentation scope, format (bulk vs vial), packaging, and lead time (approximately 20 days). Available documentation includes COA, SDS/MSDS, specification sheet, HPLC report, and LC-MS report. Research-grade is standard; API-grade is available under a signed quality agreement, and a third-party verification report can be provided where authorized.
Tesamorelin Acetate supplied through this page is intended for laboratory research use only. It is not supplied for clinical use, therapeutic use, compounding, injection, human use, resale to consumers, or any unapproved application.
Before requesting a quotation, these guides cover the specification and document questions that come up most often on this product.
FAQ
Tesamorelin (development code TH9507) is a synthetic 44-amino-acid GHRH / GRF(1-44) analog with an N-terminal trans-3-hexenoyl modification, supplied here as the acetate salt. CAS 901758-09-6 applies to the acetate and 218949-48-5 to the free base.
No. It is supplied as a research-use raw material for laboratory research and B2B sourcing projects. No dosing, administration, reconstitution, or human-use guidance is provided, and WUMO Peptide is not affiliated with any branded tesamorelin drug product.
COA, SDS/MSDS, specification sheet, HPLC report, and LC-MS report, batch-specific. Purity is quoted at greater than 99.3% by HPLC on the batch-specific COA.
Neutral vial, box packaging, or selected private-label options can be discussed for qualified projects. Labeling and market compliance remain buyer-side responsibilities.
Salt form (acetate or free base), the molecular-weight basis used on the COA (~5135.9 Da free-base equivalent versus ~5196 Da acetate salt basis), purity stated separately from peptide content, format (bulk powder by gram or 2 / 5 / 10 mg vial), and lead time, which runs approximately 20 days subject to batch and order scope.
OEM / Private Label
For finished lyophilized peptide vials with custom labels and packaging -- covering MOQ, sample or pilot evaluation, and batch documentation such as COA, sterility, and endotoxin reports -- see our private label peptide vial (OEM / ODM) service.
Use this form for pricing, technical files, sample requests, or project discussion for this product.
Need COA, SDS/MSDS, or specifications? Choose "Technical document request" in the inquiry form or mention the file name in your message.